Cellosaurus KCI-MOH1 (CVCL_2090)

Cell line name KCI-MOH1
Synonyms KciMoh-1; KCIMOH1; WSU-MOH1
Accession CVCL_2090
Resource Identification Initiative To cite this cell line use: KCI-MOH1 (RRID:CVCL_2090)
Comments Problematic cell line: Contaminated. Shown to be a HPAC derivative (PubMed=20143388). Was originally thought to originate from a 74 year old male patient with a moderately differentiated adenocarcinoma of the head of the pancreas.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Doubling time: ~70 hours (DSMZ).
Omics: Deep RNAseq analysis.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-MOH1.
Disease Pancreatic adenocarcinoma (NCIt: C8294)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_3517 (HPAC)
Sex of cell Female
Age at sampling 64Y
Category Cancer cell line
STR profile Source(s): DSMZ

Markers:
AmelogeninX
CSF1PO13
D13S31711
D16S5399,10
D5S81812
D7S82010,12
TH019.3
TPOX10,11
vWA15,17
Web pages http://www.prnewswire.com/news-releases/asterand-introduces-nine-ways-to-accelerate-cancer-research-55450592.html
http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
Publications

PubMed=9436858; DOI=10.1097/00006676-199801000-00004
Mohammad R.M., Dugan M.C., Mohamed A.N., Almatchy V.P., Flake T.M., Dergham S.T., Shields A.F., Al-Katib A., Vaitkevicius V.K., Sarkar F.H.
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
Pancreas 16:19-25(1998)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

CLPUB00416
Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

Cross-references
Cell line collections DSMZ; ACC-498
Cell line databases/resources CCLE; KCIMOH1_PANCREAS
Ontologies EFO; EFO_0006608
Biological sample resources BioSample; SAMN03151779
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM887201
GEO; GSM888274